BioSpace News Archive

-- Significance of 30% overall response rate (ORR), 6% complete responses (CR), durability and favorable safety data from KEYNOTE-695 Phase 2b trial discussed by Key Opinion Leaders (KOLs) specializing in melanoma treatment --

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the final results from its PLX9486 + sunitinib Phase 1/2 study in patients with advanced gastrointestinal stromal tumors (GIST).

Tel Aviv University and The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center announced today that, for the first time in humans, two key biological hallmarks of aging, telomere length shortening and accumulation of senescent cells, can be reversed, according to a new study.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte’s Technology Fast 500™ , a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tec

The Prostate Cancer Foundation and Movember announced two new Movember – PCF Challenge Awards.

Vivera Pharmaceuticals is excited to announce a distribution partnership with EcoGroup USA for Vivera’s BioZone, an advanced access control device intended for sanitization in high occupancy settings. BioZone is designed to combine facial recognition, integrated biometrics, and a hospital grade FDA and EPA approved organi

American Heart Association Social Impact Fund financially supports innovative solutions to the challenges that have contributed to the disproportionate effect of COVID-19 in communities of color

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Thermo Fisher Scientific, the world leader in serving science, today announced the new Thermo Scientific Tundra Cryo Transmission Electron Microscope (Cryo-TEM), a groundbreaking instrument that extends cryo-electron microscopy (cryo-EM) to more scientists by delivering industry-leading ease of use at an affordable price.

CreaGen Inc., a 17-year-old medicinal chemistry and drug discovery research service provider, has been awarded a 7-year Indefinite-Delivery/Indefinite Quantity (IDIQ) type base contract by NIAID to provide preclinical services for HIV therapeutics, marking the company’s first multi-year federal partnership.